Study Shows Predisposed Cancer Factors in Ashkenazi Jewish Women
By LabMedica International staff writers Posted on 07 Aug 2017 |
Image: A new study suggests that Ashkenazi Jewish women can benefit from genetic testing for all known breast cancer genes (Photo courtesy of the University of Washington).
Upon finding additional breast cancer mutations in Ashkenazi Jewish breast cancer patients, a new study suggests that this population of women can benefit from genetic testing for all known breast cancer genes.
There are 3 known founder-mutations in BRCA1 and BRCA2 (BRAC1/2) that severely increase the risk of breast and ovarian cancer in Ashkenazi Jewish women. In the new study, led by Mary-Claire King, PhD, of the University of Washington (Seattle, WA, USA), researchers looked for other BC-predisposing mutations in this population. They performed multiplex genomic sequencing, for all known and candidate breast cancer genes, on DNA from 1,007 women of Ashkenazi Jewish ancestry with breast cancer. Of these 1,007 patients, 903 had none of the 3 BRCA1/2 founder mutations. Of those 903 patients, seven (0.8%) carried a different mutation in BRCA1 or BRCA2 and 31 (3.4%) carried a damaging mutation in another breast cancer gene.
The study notes two limitations, including that they only sequenced genes that were known or suspected to harbor mutations that increase the risk of breast cancer.
The study, by Walsh T et al, was published July 20, 2017, by the journal JAMA Oncology.
Related Links:
University of Washington
There are 3 known founder-mutations in BRCA1 and BRCA2 (BRAC1/2) that severely increase the risk of breast and ovarian cancer in Ashkenazi Jewish women. In the new study, led by Mary-Claire King, PhD, of the University of Washington (Seattle, WA, USA), researchers looked for other BC-predisposing mutations in this population. They performed multiplex genomic sequencing, for all known and candidate breast cancer genes, on DNA from 1,007 women of Ashkenazi Jewish ancestry with breast cancer. Of these 1,007 patients, 903 had none of the 3 BRCA1/2 founder mutations. Of those 903 patients, seven (0.8%) carried a different mutation in BRCA1 or BRCA2 and 31 (3.4%) carried a damaging mutation in another breast cancer gene.
The study notes two limitations, including that they only sequenced genes that were known or suspected to harbor mutations that increase the risk of breast cancer.
The study, by Walsh T et al, was published July 20, 2017, by the journal JAMA Oncology.
Related Links:
University of Washington
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders